相似文献
1
Impact of Mutations at Amino Acid 70 in Hepatitis C Virus (HCV) Genotype 1b Core Region on Hepatocarcinogenesis following Eradication of HCV RNA.
J Clin Microbiol. 2015 Sep;53(9):3039-41. doi: 10.1128/JCM.01457-15. Epub 2015 Jul 1.
2
Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy.
J Med Virol. 2011 Jun;83(6):1016-22. doi: 10.1002/jmv.22094.
3
Amino acid substitutions in the hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by all-oral direct-acting antiviral regimens.
J Med Virol. 2018 Jun;90(6):1087-1093. doi: 10.1002/jmv.25047. Epub 2018 Feb 26.
4
Complex Association of Virus- and Host-Related Factors with Hepatocellular Carcinoma Rate following Hepatitis C Virus Clearance.
J Clin Microbiol. 2019 Jan 2;57(1). doi: 10.1128/JCM.01463-18. Print 2019 Jan.
5
Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis.
Hepatology. 2007 Nov;46(5):1357-64. doi: 10.1002/hep.21836.
6
Virological and biochemical features in elderly HCV patients with hepatocellular carcinoma: amino acid substitutions in HCV core region as predictor of mortality after first treatment.
Intervirology. 2009;52(4):179-88. doi: 10.1159/000225193. Epub 2009 Jun 17.
7
Substitution of amino acid 70 in the hepatitis C virus core region of genotype 1b is an important predictor of elevated alpha-fetoprotein in patients without hepatocellular carcinoma.
J Med Virol. 2008 Aug;80(8):1354-62. doi: 10.1002/jmv.21202.
8
Complicated relationships of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis.
Hepatology. 2012 Dec;56(6):2134-41. doi: 10.1002/hep.25949.
9
Impact of amino acid substitutions in the hepatitis C virus genotype 1b core region on liver steatosis and hepatic oxidative stress in patients with chronic hepatitis C.
Liver Int. 2010 Apr;30(4):554-9. doi: 10.1111/j.1478-3231.2009.02164.x. Epub 2009 Nov 27.
10
Amino acid substitutions in the hepatitis C Virus core region and lipid metabolism are associated with hepatocarcinogenesis in nonresponders to interferon plus ribavirin combination therapy.
Intervirology. 2013;56(1):13-21. doi: 10.1159/000339993. Epub 2012 Aug 16.
引用本文的文献
1
Subgenotyping and genetic variability of hepatitis C virus in Palestine.
PLoS One. 2019 Oct 7;14(10):e0222799. doi: 10.1371/journal.pone.0222799. eCollection 2019.
2
Complex Association of Virus- and Host-Related Factors with Hepatocellular Carcinoma Rate following Hepatitis C Virus Clearance.
J Clin Microbiol. 2019 Jan 2;57(1). doi: 10.1128/JCM.01463-18. Print 2019 Jan.
3
Frequency of Interferon-Resistance Conferring Substitutions in Amino Acid Positions 70 and 91 of Core Protein of the Russian HCV 1b Isolates Analyzed in the T-Cell Epitopic Context.
J Immunol Res. 2018 Feb 7;2018:7685371. doi: 10.1155/2018/7685371. eCollection 2018.
4
Polymorphisms in the hepatitis C virus core and its association with development of hepatocellular carcinoma.
J Biosci. 2017 Sep;42(3):509-521. doi: 10.1007/s12038-017-9695-4.
5
Viral hepatitis and liver cancer.
Philos Trans R Soc Lond B Biol Sci. 2017 Oct 19;372(1732). doi: 10.1098/rstb.2016.0274.
6
Chronic hepatitis C virus infection and pathogenesis of hepatocellular carcinoma.
Curr Opin Virol. 2016 Oct;20:99-105. doi: 10.1016/j.coviro.2016.09.010. Epub 2016 Oct 11.
7
Impact of HCV core gene quasispecies on hepatocellular carcinoma risk among HALT-C trial patients.
Sci Rep. 2016 Jun 1;6:27025. doi: 10.1038/srep27025.
本文引用的文献
1
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.
N Engl J Med. 2014 May 15;370(20):1889-98. doi: 10.1056/NEJMoa1402454. Epub 2014 Apr 11.
2
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.
N Engl J Med. 2014 Apr 17;370(16):1483-93. doi: 10.1056/NEJMoa1316366. Epub 2014 Apr 11.
3
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.
N Engl J Med. 2014 May 15;370(20):1879-88. doi: 10.1056/NEJMoa1402355. Epub 2014 Apr 10.
4
Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection.
Hepatology. 2014 Jun;59(6):2083-91. doi: 10.1002/hep.27113. Epub 2014 Apr 1.
5
Deep-sequencing analysis of the association between the quasispecies nature of the hepatitis C virus core region and disease progression.
J Virol. 2013 Dec;87(23):12541-51. doi: 10.1128/JVI.00826-13. Epub 2013 Aug 14.
6
Comparative quantitative analysis of hepatitis C mutations at amino acids 70 and 91 in the core region by the Q-Invader assay.
J Virol Methods. 2013 Apr;189(1):221-7. doi: 10.1016/j.jviromet.2012.10.011. Epub 2012 Nov 2.
7
Complicated relationships of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis.
Hepatology. 2012 Dec;56(6):2134-41. doi: 10.1002/hep.25949.
8
Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders.
Hepatology. 2012 Mar;55(3):742-8. doi: 10.1002/hep.24724. Epub 2012 Jan 30.
9
Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy.
J Med Virol. 2011 Jun;83(6):1016-22. doi: 10.1002/jmv.22094.
10
Characteristic mutations in hepatitis C virus core gene related to the occurrence of hepatocellular carcinoma.
Cancer Sci. 2009 Dec;100(12):2465-8. doi: 10.1111/j.1349-7006.2009.01338.x.
Zotero 插件